EUVIMEDEUVIMED entdecken
Fallbericht

A case of immune checkpoint inhibitor-associated hemophagocytosis after initiation of atezolizumab plus bevacizumab therapy for advanced hepatocellular carcinoma

Hisashi Hidaka, Hirotoshi Kamata, Haruki Uojima, Shuichiro Iwasaki, Junki Iida, Takahide Nakazawa, Chika Kusano

Clinical Journal of Gastroenterology · 2024

DOI: 10.1007/s12328-024-02040-8 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Clinical Journal of Gastroenterology, 2024. Verfasst von Hisashi Hidaka und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Internal Medicine, Kitasato University School of Medicine, Kitasato University Hospital, 1-15-1 Kitasato, Minami-Ku, …. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Bevacizumab, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 9 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A woman in the 70s with a decreased appetite and weight loss (4 kg) in the last 3 months was referred to our hospital. An enhanced CT scan of the abdomen showed a hepatocellular carcinoma (HCC) of 83 mm in diameter of the liver with metastasis to the para-aortic lymph nodes, the left adrenal gland, and the right lower lung lobe (cStage IVb). She was started on atezolizumab + bevacizumab (Atezo-Bev) therapy. A week after the treatment, she began to have a decreased appetite, fever in the 39 °C range, subcutaneous bleeding, and a slight headache when walking. So she was urgently admitted to our hospital. We diagnosed her as having a hemophagocytic syndrome and administered 1 g steroid pulse therapy for 3 days followed by 1 mg/kg of prednisone. Her condition began to improve. This is the first case report of a hemophagocytic syndrome in a patient with HCC treated with Atezo-Bev.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsBevacizumabAntibodies, Monoclonal, HumanizedLymphohistiocytosis, HemophagocyticAntineoplastic Combined Chemotherapy ProtocolsImmune Checkpoint InhibitorsHumansFemaleAged

Stichwörter der Autor:innen

Atezolizumab plus bevacizumab (Atezo-Bev)HemophagocytosisHepatocellular carcinoma (HCC)Immune-related adverse events (irAEs)

Substanzen

atezolizumabBevacizumabAntibodies, Monoclonal, HumanizedImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Gastroenterology, Internal Medicine, Kitasato University School of Medicine, Kitasato University Hospital, 1-15-1 Kitasato, Minami-Ku, Sagamihara, Kanagawa, 252-0374, Japan. hisashi7@kitasato-u.ac.jp.
  • Department of Hematology, Kitasato University School of Medicine, Kanagawa, Japan.
  • Department of Gastroenterology, Internal Medicine, Kitasato University School of Medicine, Kitasato University Hospital, 1-15-1 Kitasato, Minami-Ku, Sagamihara, Kanagawa, 252-0374, Japan.

Zitieren

APA

Hidaka, H., Kamata, H., Uojima, H., Iwasaki, S., Iida, J., Nakazawa, T., & Kusano, C. (2024). A case of immune checkpoint inhibitor-associated hemophagocytosis after initiation of atezolizumab plus bevacizumab therapy for advanced hepatocellular carcinoma. Clinical Journal of Gastroenterology. https://doi.org/10.1007/s12328-024-02040-8

Vancouver

Hidaka H, Kamata H, Uojima H, Iwasaki S, Iida J, Nakazawa T, et al. A case of immune checkpoint inhibitor-associated hemophagocytosis after initiation of atezolizumab plus bevacizumab therapy for advanced hepatocellular carcinoma. Clinical Journal of Gastroenterology. 2024. doi:10.1007/s12328-024-02040-8

BibTeX
@article{Hidaka2024,
  author = {Hidaka, Hisashi and Kamata, Hirotoshi and Uojima, Haruki and Iwasaki, Shuichiro and Iida, Junki and Nakazawa, Takahide and Kusano, Chika},
  title = {A case of immune checkpoint inhibitor-associated hemophagocytosis after initiation of atezolizumab plus bevacizumab therapy for advanced hepatocellular carcinoma},
  journal = {Clinical Journal of Gastroenterology},
  year = {2024},
  doi = {10.1007/s12328-024-02040-8}
}
Kostenlos starten →